Provided is a somatostatin receptor subtype 2 agonist. A compound disclosed in the present invention that is represented by general formula (I) (wherein each symbol has the same meaning as defined in the description) or a salt thereof is a low molecular compound having a strong agonistic activity to somatostatin receptor subtype 2. The compound according to the present invention can be orally administered and, therefore, can be easily taken and contribute to the reduction of patient's pain associated with a therapeutic treatment. Moreover, the compound according to the present invention has sufficiently weak hERG inhibitory activity and/or phospholipidosis effect, compared with the SSTR2 agonistic activity thereof, and, therefore, can inhibit or suppress side effects caused by the aforesaid activity and/or effect.
